Pomerantz LLP is investigating Agios Pharmaceuticals and some of its executives for possible securities fraud following the company's announcement that its Phase 2 trial for tebapivat in sickle cell disease patients failed to meet expectations. The trial results led Agios to halt development of the drug, causing the stock to drop 6.74% on July 21, 2026. The investigation aims to determine if the company misled investors or engaged in unlawful practices. Investors affected are encouraged to contact the law firm for potential class action participation.
Ethereum co-founder Vitalik Buterin has proposed EIP-8141, aiming to simplify Ethereum wallets by allowing multiple actions in one transaction, supporting key rotation to reduce reliance on seed phrases, and enabling apps to pay users' gas fees. This...
Since the Federal Reserve's establishment in 1913, the US dollar has lost about 97% of its purchasing power due to inflation and major economic events. This decline has increased interest in Bitcoin, which offers a capped supply and potential protect...
In Q2 2024, Goldman Sachs held the largest institutional position in XRP ETFs, with $87.45 million in exposure, far ahead of Jane Street and Millennium Management. These holdings represent about 12.4% of the total $1.48 billion in XRP ETF net assets,...
Berlin's state government refused to pay a 30 Bitcoin ransom (about $2.4 million) demanded by the Rhysida ransomware group, leading to the release of 5.7 terabytes of stolen data on the dark web. The cyberattack, detected on August 14, disrupted two ...
Bitcoin traded near $79,972, up 0.43% in 24 hours, with optimism for reaching $85,000 fueled by strong ETF inflows and bullish market sentiment. The global crypto market cap rose to $2.72 trillion, led by gains in Solana, Ethereum, XRP, and BNB. Key ...
